

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

Deadline: 14.10.2022

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{Tot}	N _{Out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(1) Sodium	[mmol/L]				379								0								379	370	98%
Samples and groups																							
Sample A		128	1,9	1,4	379								0	CRV	128,3	1,9	5%	121	135	379	373	98%	
(2) Indirect ISE		128	1,8	1,4	335	0															335		
(3) Direct ISE		129	2,1	1,6	43	0															43		
Other					1	0															1		
														1x 99									
Sample B		129	1,9	1,5	379								0	CRV	130,7	2,0	5%	124	138	379	375	99%	
(2) Indirect ISE		129	1,8	1,4	335	0															335		
(3) Direct ISE		130	2,6	2,0	43	0															43		
Other					1	0															1		
														1x 99									
(2) Potassium	[mmol/L]				379								0								379	373	98%
Samples and groups																							
Sample A		3,39	0,05	1,7	379								0	CRV	3,353	0,050	7%	3,11	3,59	379	373	98%	
(2) Indirect ISE		3,39	0,05	1,6	336	0															336		
(3) Direct ISE		3,39	0,06	1,8	42	0															42		
Other					1	0															1		
														1x 99									
Sample B		6,31	0,11	1,8	379								0	CRV	6,28	0,100	7%	5,84	6,72	379	377	99%	
(2) Indirect ISE		6,31	0,11	1,8	336	0															336		
(3) Direct ISE		6,31	0,13	2,0	42	0															42		
Other					1	0															1		
														1x 99									
(3) Chloride	[mmol/L]				379								379	375	99%						0		
Samples and groups																							
Sample A		112	3,0	2,7	379		CVP	112	0,38	7%	104	120	379	376	99%						0		
(3) Indirect ISE		112	3,1	2,8	338	0							338										
(4) Direct ISE		111	2,2	2,0	40	0							40										
Other					1	0							1										
							1x 99																
Sample B		115	3,4	2,9	379		CVP	115	0,43	7%	106	124	379	377	99%						0		
(3) Indirect ISE		115	3,5	3,0	338	0							338										
(4) Direct ISE		115	2,8	2,4	40	0							40										
Other					1	0							1										
							1x 99																
(4) Calcium	[mmol/L]				357																357	352	99%
Samples and groups																							
Sample A		2,90	0,06	2,3	357								0	CRV	2,926	0,047	8%	2,69	3,17	357	355	99%	
(2) Phot. with o-cresolftalexon		2,91	0,08	2,8	30	0															30		
(3) Photom. with arsenazo III		2,89	0,07	2,4	205	0															205		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(4) Calcium	[mmol/L]				357							0									357	352	99%
Samples and groups																							
Sample A		2,90	0,06	2,3	357							0	CRV	2,926	0,047	8%	2,69	3,17		357	355	99%	
(4) Photomet. with NM-BAPTA		2,92	0,05	1,8	121	0														121			
Other					1	0															1		
Sample B		2,77	0,06	2,4	357							0	1x99 CRV	2,795	0,046	8%	2,57	3,02		357	353	99%	
(2) Phot. with o-cresolftalexon		2,75	0,08	3,2	30	0														30			
(3) Photom. with arsenazo III		2,77	0,06	2,4	205	0														205			
(4) Photomet. with NM-BAPTA		2,78	0,05	2,1	121	0														121			
Other					1	0															1		
													1x99										
(5) Inorganic phosphate	[mmol/L]				346							346	337	97%							0		
Samples and groups																							
Sample A		1,03	0,03	3,4	346	CVP	1,03	,0046	10%	0,927	1,14	346	337	97%							0		
(1) UV-molybdate method		1,03	0,03	3,4	337	0						337											
(3) Molybdate-vanadate method		1,03	0,03	2,9	5	0						5											
Other					4	0						4											
Sample B		1,83	0,05	2,9	346	4x2 CVP	1,83	,0071	10%	1,64	2,02	346	343	99%							0		
(1) UV-molybdate method		1,83	0,05	2,9	337	0						337											
(3) Molybdate-vanadate method		1,84	0,08	4,4	5	0						5											
Other					4	0						4											
						4x2																	
(6) Iron	[µmol/L]				329							329	328	100%							0		
Samples and groups																							
Sample A		41,1	1,0	2,4	329	CVP	41,1	0,13	15%	34,9	47,3	329	328	100%							0		
(2) Method with ferrozine/ferene		41,2	0,98	2,4	278	0						278											
(4) Method with TPTZ		40,8	1,0	2,5	50	0						50											
Other					1	0						1											
Sample B		37,7	1,1	2,8	329	1x99 CVP	37,7	0,14	15%	32	43,4	329	328	100%							0		
(2) Method with ferrozine/ferene		37,8	1,1	2,9	278	0						278											
(4) Method with TPTZ		37,1	0,88	2,4	50	0						50											
Other					1	0						1											
						1x99																	
(7) Magnesium	[mmol/L]				340							0									340	329	97%
Samples and groups																							
Sample A		0,815	0,02	3,6	340							0	CRV	0,783	0,012	15%	0,665	0,901		340	337	99%	
(2) Photometry		0,820	0,02	3,4	263	0														263			
(4) UV enzyme method		0,797	0,02	3,3	76	0														76			
Other					1	0															1		
Sample B		0,520	0,03	5,8	340							0	1x99 CRV	0,488	0,011	asym.	0,414	0,591		340	331	97%	
(2) Photometry		0,527	0,02	5,2	263	0														263			
(4) UV enzyme method		0,494	0,02	4,4	76	0														76			
Other					1	0															1		
													1x99										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability										Traceability										
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(8) Lithium					45							0								45	38	84%
Samples and groups	[mmol/L]																					
Sample A		1,45	0,06	4,7	45							0	CRV	1,489	0,022	12%	1,31	1,67	45	43	96%	
(2) AAS		1,48	0,12	8,1	5	0													5			
(3) ISE		1,48	0,04	3,1	12	0													12			
(4) Photometry		1,43	0,05	3,6	24	0													24			
Other					4	0													4			
Sample B		1,01	0,06	6,2	45							0	CRV	1,063	0,016	12%	0,935	1,2	45	38	84%	
(2) AAS		1,01	0,12	12	5	0													5			
(3) ISE		1,04	0,02	2,4	12	0													12			
(4) Photometry		0,994	0,06	6,4	24	0													24			
Other					4	0													4			
(9) Total protein					365							0							365	359	98%	
Samples and groups	[g/L]																					
Sample A		71,0	1,7	2,4	365							0	CRV	72,1	1,7	9%	65,6	78,6	365	362	99%	
(1) Biuret		71,0	1,7	2,4	365	0													365			
Sample B		87,5	2,3	2,6	365							0	CRV	88,4	2,0	9%	80,4	96,4	365	361	99%	
(1) Biuret		87,5	2,3	2,6	365	0													365			
(10) Albumin					362							362	356	98%					0			
Samples and groups	[g/L]																					
Sample A		45,2	1,6	3,5	362	CVP	45,2	0,21	10%	40,6	49,8	362	359	99%					0			
(1) BCG		45,3	1,5	3,3	338	0						338										
(2) BCP		43,2	1,7	4,0	24	0						24										
Sample B		55,5	2,0	3,6	362	CVP	55,5	0,26	10%	49,9	61,1	362	357	99%					0			
(1) BCG		55,6	1,9	3,4	338	0						338										
(2) BCP		53,8	1,9	3,5	24	0						24										
(11) Osmolality					137							137	135	99%					0			
Samples and groups	[mmol/kg]																					
Sample A		299	5,3	1,8	137	CVP	299	1,1	5%	284	314	137	136	99%					0			
(1) Osmometer		300	5,3	1,8	135	0						135										
Other					2	0						2										
Sample B		291	6,3	2,2	137	CVP	291	1,3	5%	276	306	137	135	99%					0			
(1) Osmometer		291	6,2	2,1	135	0						135										
Other					2	0						2										
(12) Lactate					164							164	159	97%					0			
Samples and groups	[mmol/L]																					
Sample A		2,00	0,08	4,5	164	CVP	2,0	0,017	15%	1,7	2,3	164	160	98%					0			
(1) UV enzyme method		2,00	0,07	3,6	65	0						65										
(2) Enzyme electrodes		2,14	0,20	9,4	10	0						10										
(3) Photometric enzyme method		2,00	0,09	4,7	89	0						89										
Sample B		2,01	0,09	4,8	164	CVP	2,01	0,019	15%	1,7	2,32	164	160	98%					0			
(1) UV enzyme method		2,01	0,08	4,2	65	0						65										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(12) Lactate					164							164	159	97%							0		
Samples and groups	[mmol/L]																						
Sample B		2,01	0,09	4,8	164	CVP	2,01	0,019	15%	1,7	2,32	164	160	98%							0		
(2) Enzyme electrodes		2,18	0,21	9,8	10							10											
(3) Photometric enzyme method		2,00	0,09	4,9	89							89											
(13) Bilirubin total					385																385	381	99%
Samples and groups	[µmol/L]																						
Sample A		28,4	2,6	9,0	385							0		CRV	27,7	0,70	21%	21,8	33,6		385	381	99%
(1) Jendrassik-Gróf		28,7	2,8	9,8	47																47		
(2) DCA, DPD		28,2	2,6	9,0	294																294		
(4) Oxidation-reduction methods		29,8	1,8	5,9	42																42		
Other					2																2		
Sample B		51,5	3,8	7,3	385							0		CRV	51,5	1,1	21%	40,6	62,4		385	385	100%
(1) Jendrassik-Gróf		51,9	3,8	7,4	47																47		
(2) DCA, DPD		51,1	3,7	7,2	294																294		
(4) Oxidation-reduction methods		53,7	3,0	5,6	42																42		
Other					2																2		
														2x 99									
(15) Cholesterol					373							6	5	83%							367	355	97%
Samples and groups	[mmol/L]																						
Sample A		3,89	0,11	2,8	373							6	5	83%							367	358	98%
(1) Enzyme method CHOD-PAP		3,89	0,11	2,7	367									CRV	3,906	0,039	9%	3,55	4,26		367		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)		3,58	0,19	5,2	6	0	CVPG	3,58	0,26	7%	3,32	3,84								6			
Sample B		5,00	0,14	2,8	373							6	6	100%							367	361	98%
(1) Enzyme method CHOD-PAP		5,01	0,14	2,8	367									CRV	5,087	0,051	9%	4,62	5,55		367		
(1) Enzyme method CHOD-PAP; (149) Siemens (Dade, BN, Dimension)		4,65	0,09	2,1	6	0	CVPG	4,65	0,13	7%	4,32	4,98								6			
														2x 99									
(16) Glucose					388																388	386	99%
Samples and groups	[mmol/L]																						
Sample A		3,76	0,11	3,0	388							0		CRV	3,89	0,039	asym.	3,46	4,21		388	387	100%
(1) GOD photometry		3,82	0,13	3,3	70																70		
(3) Method with hexokinase		3,75	0,11	2,9	316																316		
Other					2																2		
Sample B		7,57	0,19	2,5	388							0		CRV	7,846	0,078	asym.	6,98	8,48		388	387	100%
(1) GOD photometry		7,63	0,22	2,9	70																70		
(3) Method with hexokinase		7,55	0,18	2,4	316																316		
Other					2																2		
														2x 2									
(17) Uric acid					381																381	380	100%
Samples and groups	[µmol/L]																						
Sample A		454	12	2,5	381							0		CRV	456,3	4,6	12%	401	512		381	380	100%
(2) Enzyme-photomet. m.		454	12	2,5	381																381		
Sample B		519	13	2,4	381							0		CRV	514,4	5,1	12%	452	577		381	380	100%
(2) Enzyme-photomet. m.		519	13	2,4	381																381		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(18) Urea					386							0								386	381	99%	
Samples and groups	[mmol/L]																						
Sample A		31,1	1,1	3,7	386							0		CRV	31,96	0,32	15%	27,1	36,8	386	383	99%	
(1) UV enzymatic m.(GMD)		31,1	1,1	3,7	384	0														384			
Other					2	0														2			
Sample B		15,6	0,60	3,8	386							0		2x2 CRV	15,83	0,16	15%	13,4	18,3	386	383	99%	
(1) UV enzymatic m.(GMD)		15,6	0,60	3,8	384	0														384			
Other					2	0														2			
(19) Creatinine					387							0								387	380	98%	
Samples and groups	[µmol/L]																						
Sample A		121	4,9	4,0	387							0		CRV	119,6	1,7	13%	104	136	387	382	99%	
(1) Jaffe		123	5,6	4,6	172	0														172			
(3) Enzyme		120	4,0	3,4	215	0														215			
Sample B		404	13	3,3	387							0		CRV	397,6	4,0	13%	345	450	387	385	99%	
(1) Jaffe		404	17	4,3	172	0														172			
(3) Enzyme		404	10	2,6	215	0														215			
(20) Triacylglycerols					371							0								371	368	99%	
Samples and groups	[mmol/L]																						
Sample A		1,80	0,06	3,4	371							0		CRV	1,771	0,018	15%	1,5	2,04	371	368	99%	
(1) Photometric enzyme (GPO-PAP)		1,80	0,06	3,4	362	0														362			
(2) Enzymatic UV method		1,82	0,06	3,7	9	0														9			
Sample B		1,72	0,06	3,7	371							0		CRV	1,72	0,017	15%	1,46	1,98	371	371	100%	
(1) Photometric enzyme (GPO-PAP)		1,72	0,06	3,7	362	0														362			
(2) Enzymatic UV method		1,71	0,05	3,0	9	0														9			
(21) ALP					378							370	366	99%						378	377	100%	
Samples and groups	[µkat/L]																						
Sample A		3,47	0,29	8,2	378							370	366	99%	CRV	3,62	0,100	20%	2,89	4,35	378	377	100%
(3) IFCC method; (1) Abbott		3,63	0,14	3,8	87	0	CVPG	3,64	0,037	15%	3,09	4,19							87				
(3) IFCC method		3,47	0,29	8,2	377	0																377	
(3) IFCC method; (46) Erba Lachema		3,67	0,17	4,7	13	0	CVPG	3,67	0,12	15%	3,11	4,23							13				
(3) IFCC method; (49) BioVendor		3,44	0,24	7,1	7	0	CVPG	3,44	0,24	15%	2,92	3,96							7				
(3) IFCC method; (58) Beckman Coulter (AU)		3,81	0,23	5,9	55	0	CVPG	3,81	0,075	15%	3,23	4,39							55				
(3) IFCC method; (60) Roche		3,28	0,14	4,4	145	0	CVPG	3,28	0,029	15%	2,78	3,78							145				
(3) IFCC method; (149) Siemens (Dade, BN, Dimension)		3,42	0,19	5,4	8	0	CVPG	3,42	0,14	15%	2,9	3,94							8				
(3) IFCC method; (162) Siemens (Atellica)		3,23	0,11	3,5	21	0	CVPG	3,23	0,061	15%	2,74	3,72							21				
(3) IFCC method; (177) Mindray		3,68	0,26	7,1	11	0	CVPG	3,68	0,19	15%	3,12	4,24							11				
(3) IFCC method; (178) DiaSys		3,66	0,20	5,5	6	0	CVPG	3,66	0,28	15%	3,11	4,21							6				
(3) IFCC method; (179) Siemens		3,27	0,22	6,7	16	0	CVPG	3,27	0,13	15%	2,77	3,77							16				
Other					1	0														1			
Sample B		3,17	0,24	7,6	378							370	368	99%	1x1 CRV	3,373	0,094	20%	2,69	4,05	378	377	100%
(3) IFCC method; (1) Abbott		3,30	0,14	4,2	87	0	CVPG	3,3	0,037	15%	2,8	3,8							87				

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(21) ALP					378							370	366	99%						378	377	100%	
Samples and groups	[µkat/L]																						
Sample B		3,17	0,24	7,6	378							370	368	99%	CRV	3,373	0,094	20%	2,69	4,05	378	377	100%
(3) IFCC method		3,17	0,24	7,5	377	0																	377
(3) IFCC method; (46) Erba Lachema		3,37	0,21	6,3	13	0	CVPG	3,37	0,14	15%	2,86	3,88		13									
(3) IFCC method; (49) BioVendor		3,12	0,19	6,2	7	0	CVPG	3,12	0,19	15%	2,65	3,59		7									
(3) IFCC method; (58) Beckman Coulter (AU)		3,42	0,19	5,5	55	0	CVPG	3,42	0,063	15%	2,9	3,94		55									
(3) IFCC method; (60) Roche		3,02	0,13	4,5	145	0	CVPG	3,02	0,027	15%	2,56	3,48		145									
(3) IFCC method; (149) Siemens (Dade, BN, Dimension)		3,09	0,11	3,6	8	0	CVPG	3,09	0,085	15%	2,62	3,56		8									
(3) IFCC method; (162) Siemens (Atellica)		2,94	0,09	3,1	21	0	CVPG	2,94	0,049	15%	2,49	3,39		21									
(3) IFCC method; (177) Mindray		3,32	0,21	6,3	11	0	CVPG	3,32	0,15	15%	2,82	3,82		11									
(3) IFCC method; (178) DiaSys		3,33	0,04	1,3	6	0	CVPG	3,33	0,062	15%	2,83	3,83		6									
(3) IFCC method; (179) Siemens		2,99	0,18	6,1	16	0	CVPG	2,99	0,11	15%	2,54	3,44		16									
Other					1	0								1									1
								1x 1/1, 1x 3/5, 4x 3/12, 1x 3/121, 2x 3/158							1x 1								
(22) alpha-amylase					364							6	6	100%						358	347	97%	
Samples and groups	[µkat/L]																						
Sample A		5,42	0,35	6,5	364							6	6	100%						358	353	99%	
(1) IFCC method		5,41	0,34	6,3	356	0									CRV	5,35	0,16	15%	4,54	6,16			356
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)		6,51	0,19	2,8	6	0	CVPG	6,51	0,26	8,8%	5,93	7,09		6									
Other					2	0																	2
															2x 99								
Sample B		1,96	0,08	4,1	364							6	6	100%						358	352	98%	
(1) IFCC method		1,96	0,07	4,0	356	0									CRV	2,06	0,056	15%	1,75	2,37			356
(1) IFCC method; (149) Siemens (Dade, BN, Dimension)		2,08	0,07	3,4	6	0	CVPG	2,08	0,097	8,8%	1,89	2,27		6									
Other					2	0																	2
															2x 99								
(23) AST					387							0								387	380	98%	
Samples and groups	[µkat/L]																						
Sample A		1,78	0,08	4,7	387							0			CRV	1,771	0,045	15%	1,5	2,04	387	383	99%
(1) IFCC method		1,78	0,08	4,7	387	0																	387
Sample B		3,21	0,15	4,6	387							0			CRV	3,141	0,069	15%	2,66	3,62	387	384	99%
(1) IFCC method		3,21	0,15	4,6	387	0																	387
(24) ALT					387							0								387	386	100%	
Samples and groups	[µkat/L]																						
Sample A		2,21	0,12	5,5	387							0			CRV	2,213	0,051	15%	1,88	2,55	387	386	100%
(1) IFCC method		2,21	0,12	5,5	387	0																	387
Sample B		2,70	0,15	5,6	387							0			CRV	2,716	0,060	15%	2,3	3,13	387	386	100%
(1) IFCC method		2,70	0,15	5,6	387	0																	387
(26) CK					351							0								351	345	98%	
Samples and groups	[µkat/L]																						
Sample A		6,68	0,41	6,2	351							0			CRV	7,12	0,18	20%	5,69	8,55	351	348	99%
(1) IFCC method		6,68	0,41	6,2	351	0																	351
Sample B		2,50	0,14	5,4	351							0			CRV	2,66	0,068	20%	2,12	3,2	351	348	99%

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(26) CK					351							0									351	345	98%	
Samples and groups	[µkat/L]																							
Sample B		2,50	0,14	5,4	351							0	CRV	2,66	0,068	20%	2,12	3,2		351	348	99%		
(1) IFCC method		2,50	0,14	5,4	351	0															351			
(27) gamma-GT					382							0									382	374	98%	
Samples and groups	[µkat/L]																							
Sample A		1,27	0,04	3,7	382							0	CRV	1,32	0,038	15%	1,12	1,52		382	375	98%		
(1) IFCC method		1,27	0,04	3,7	381	0															381			
Other					1	0																1		
Sample B		1,30	0,04	3,7	382							0	CRV	1,375	0,037	15%	1,16	1,59		382	377	99%		
(1) IFCC method		1,30	0,04	3,7	381	0															381			
Other					1	0																1		
													1x0											
(28) LD					281							0									281	280	100%	
Samples and groups	[µkat/L]																							
Sample A		6,08	0,19	3,2	281							0	CRV	6,04	0,13	18%	4,95	7,13		281	280	100%		
(3) IFCC method		6,08	0,19	3,2	281	0															281			
Sample B		6,33	0,20	3,2	281							0	CRV	6,2	0,14	18%	5,08	7,32		281	280	100%		
(3) IFCC method		6,33	0,20	3,2	281	0															281			
(29) Lipase					189							174	171	98%								0		
Samples and groups	[µkat/L]																							
Sample A		1,21	0,08	7,2	189							174	171	98%								0		
(0) Not specified; (1) Abbott		1,22	0,05	4,6	32	0	CVPG	1,22	0,024	24%	0,927	1,52									32			
(0) Not specified; (58) Beckman Coulter (AU)		1,22	0,04	3,9	34	0	CVPG	1,22	0,020	24%	0,927	1,52									34			
(0) Not specified; (60) Roche		1,17	0,05	4,8	77	0	CVPG	1,17	0,016	24%	0,889	1,46									77			
(0) Not specified; (116) Sentinel Diagnostics		1,20	0,06	5,6	6	0	CVPG	1,2	0,093	24%	0,912	1,49									6			
(0) Not specified; (162) Siemens (Atellica)		1,32	0,03	2,4	17	0	CVPG	1,32	0,019	24%	1	1,64									17			
(0) Not specified; (179) Siemens		1,33	0,07	5,6	8	0	CVPG	1,33	0,056	24%	1,01	1,65									8			
Other					15	0																0		
Sample B		1,47	0,11	7,2	189							174	174	100%								0		
(0) Not specified; (1) Abbott		1,41	0,07	5,0	32	0	CVPG	1,41	0,031	24%	1,07	1,75									32			
(0) Not specified; (58) Beckman Coulter (AU)		1,44	0,05	3,6	34	0	CVPG	1,44	0,022	24%	1,09	1,79									34			
(0) Not specified; (60) Roche		1,45	0,06	4,6	77	0	CVPG	1,45	0,019	24%	1,1	1,8									77			
(0) Not specified; (116) Sentinel Diagnostics		1,47	0,05	3,5	6	0	CVPG	1,47	0,073	24%	1,11	1,83									6			
(0) Not specified; (162) Siemens (Atellica)		1,66	0,05	3,6	17	0	CVPG	1,66	0,035	24%	1,26	2,06									17			
(0) Not specified; (179) Siemens		1,69	0,13	7,5	8	0	CVPG	1,69	0,096	24%	1,28	2,1									8			
Other					15	0																0		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AKS4/22 - Basic Clinical Chemistry - Serum

Deadline: 14.10.2022

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(30) Cholinesterase					119							119	107	90%									0
Samples and groups	[µkat/L]																						
Sample A		119	5,4	4,5	119	CVP	119	1,2	12%	104	134	119	107	90%									0
(1) Standard method		119	5,4	4,5	119	0						119											
Sample B		165	8,0	4,8	119	CVP	165	1,8	12%	145	185	119	107	90%									0
(1) Standard method		165	8,0	4,8	119	0						119											
(31) Albumin (elpho)					89							89	84	94%									0
Samples and groups	[-]																						
Sample A		0,625	0,04	7,0	89	CVP	0,625	0,012	15%	0,531	0,719	89	87	98%									0
(0) Not specified		0,625	0,04	7,0	89	1						89											
Sample B		0,623	0,05	8,8	89	CVP	0,623	0,014	15%	0,529	0,717	89	84	94%									0
(0) Not specified		0,623	0,05	8,8	89	1						89											
(32) gamma-globulin (elpho)					89							89	86	97%									0
Samples and groups	[-]																						
Sample A		0,136	0,01	9,5	89	CVP	0,136	,0034	30%	0,095	0,177	89	86	97%									0
(0) Not specified		0,136	0,01	9,5	89	1						89											
Sample B		0,131	0,01	12	89	CVP	0,131	,0043	30%	0,091	0,171	89	87	98%									0
(0) Not specified		0,131	0,01	12	89	1						89											
(35) alpha-amylase pancreatic					113							113	112	99%									0
Samples and groups	[µkat/L]																						
Sample A		4,68	0,21	4,5	113	CVP	4,68	0,049	18%	3,83	5,53	113	112	99%									0
(1) With IFCC calibration		4,68	0,21	4,5	113	0						113											
Sample B		1,28	0,06	4,7	113	CVP	1,28	0,014	18%	1,04	1,52	113	113	100%									0
(1) With IFCC calibration		1,28	0,06	4,7	113	0						113											
(36) Calcium ionised					66							66	62	94%									0
Samples and groups	[mmol/L]																						
Sample A		1,91	0,08	4,7	66	CVP	1,91	0,027	10%	1,71	2,11	66	62	94%									0
(2) Direct ISE		1,91	0,08	4,4	61	0						61											
Other					5	0						5											
Sample B		1,65	0,06	3,7	66	CVP	1,65	0,019	10%	1,48	1,82	66	62	94%									0
(2) Direct ISE		1,66	0,06	3,6	61	0						61											
Other					5	0						5											
							2x 0, 3x 1																

st_kn_np

End of report

Printed: 24.10.2022